The funding will help support a Phase 1 trial that, if successful, could improve the quality of life for patients at Children’s Hospital of Georgia and beyond.
The first in-human study of a new immunotherapy that blocks a natural enzyme that tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life...